TABLE II.
IDEA trial summary
| Variable | Trial name | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| SCOT52 (U.K., NZ, Denmark, Spain, Australia, Sweden) | IDEA France53 (France) | TOSCA54 (Italy) | ACHIEVE55 (Japan) | CALGB/SWOG23 (U.S.A., Canada) | HORG56 (Greece) | Overall | ||
| Stage III cases (n) | 3983 | 2010 | 2402 | 1291 | 2440 | 708 | 12,834 | |
|
| ||||||||
| Risk group (%) | ||||||||
| T1–3/N1 | 51.0 | 62.0 | 65.5 | 55.6 | 63.6 | 59.1 | 58.7 | |
| T4, N2, or both | 49.0 | 38.0 | 34.5 | 44.4 | 36.4 | 40.9 | 41.3 | |
|
| ||||||||
| Chemotherapy regimen (%) | ||||||||
| CAPOX | 66.5 | 10.0 | 34.0 | 75.1 | 0 | 58.2 | 39.5 | |
| FOLFOX | 33.5 | 90.0 | 66.0 | 24.9 | 100 | 41.8 | 60.5 | |
| CAPOX vs. mFOLFOX6 | CAPOX vs. mFOLFOX6 | CAPOX vs. mFOLFOX4 | CAPOX vs. mFOLFOX6 | mFOLFOX6 | CAPOX vs. mFOLFOX4 | |||
|
| ||||||||
| 3-Year disease-free survival | ||||||||
| With 3 months’ therapy (%) | 76.7 | 72 | 78.8 | 79.5 | 34.9 Months | 47.5 Months | 74.6 | |
| With 6 months’ therapy (%) | 77.1 | 76 | 78.7 | 77.9 | 75.5 | |||
| Median follow-up (months) | 36.8 | 51.3 | 61.7 | 36.7 | 41.8 | |||
|
| ||||||||
| Grade 2 or greater neuropathy (%) | FOLFOX | CAPOX | ||||||
| With 3 months’ therapy | 25 | 36 | 9 | 14 | 16.6 | 14.2 | ||
| With 6 months’ therapy | 58 | 66 | 31 | 36 | 47.7 | 44.9 | ||
CALGB = Cancer and Leukemia Group B; SWOG = Southwest Oncology Group; HORG = Hellenic Oncology Research Group; CAPOX = capecitabine–oxaliplatin; FOLFOX = infusional 5-fluorouracil–leucovorin–oxaliplatin; mFOLFOX = modified FOLFOX.